Cangrelor: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Cangrelor. Educational only — not medical advice.
Labeled uses
Cangrelor for injection is indicated as an adjunct to percutaneous coronary intervention (PCI) to reduce the risk of periprocedural myocardial infarction (MI), repeat coronary revascularization, and stent thrombosis (ST) in patients who have not been treated with a P2Y12 platelet inhibitor and are not being given a glycoprotein IIb/IIIa inhibitor [see Clinical Studies (14.1) ].
Source: FDA labeling via NIH DailyMed (set c86264c2…). Not affiliated with FDA or NIH.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.